Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Joseph W. Franses; Mir Lim; Adam M. Burgoyne; Kabir Mody; Jochen Lennerz; Jeremy Chang; Robin Imperial; Stacey N. Dybel; Thi M. Dinh; Jude Masannat; Caroline M. Weipert; David Hsiehchen

doi:10.1093/oncolo/oyac189

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Joseph W. Franses, Mir Lim, Adam M. Burgoyne, Kabir Mody, Jochen Lennerz, Jeremy Chang, Robin Imperial, Stacey N. Dybel, Thi M. Dinh, Jude Masannat, Caroline M. Weipert, David Hsiehchen

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article › peer-review

Abstract

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

Original language	English (US)
Pages (from-to)	E908-E911
Journal	Oncologist
Volume	27
Issue number	11
DOIs	https://doi.org/10.1093/oncolo/oyac189
State	Published - Nov 2022

Keywords

hepatocellular carcinoma
liquid biopsy
tumor mutational burden

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/oncolo/oyac189

Cite this

@article{fbbe46a77fa1467ea03e2eb00d8cbcff,

title = "Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma",

abstract = "Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.",

keywords = "hepatocellular carcinoma, liquid biopsy, tumor mutational burden",

author = "Franses, {Joseph W.} and Mir Lim and Burgoyne, {Adam M.} and Kabir Mody and Jochen Lennerz and Jeremy Chang and Robin Imperial and Dybel, {Stacey N.} and Dinh, {Thi M.} and Jude Masannat and Weipert, {Caroline M.} and David Hsiehchen",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press.",

year = "2022",

month = nov,

doi = "10.1093/oncolo/oyac189",

language = "English (US)",

volume = "27",

pages = "E908--E911",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "11",

}

TY - JOUR

T1 - Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

AU - Franses, Joseph W.

AU - Lim, Mir

AU - Burgoyne, Adam M.

AU - Mody, Kabir

AU - Lennerz, Jochen

AU - Chang, Jeremy

AU - Imperial, Robin

AU - Dybel, Stacey N.

AU - Dinh, Thi M.

AU - Masannat, Jude

AU - Weipert, Caroline M.

AU - Hsiehchen, David

PY - 2022/11

Y1 - 2022/11

N2 - Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

AB - Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

KW - hepatocellular carcinoma

KW - liquid biopsy

KW - tumor mutational burden

UR - http://www.scopus.com/inward/record.url?scp=85141890061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141890061&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyac189

DO - 10.1093/oncolo/oyac189

M3 - Article

C2 - 36103364

AN - SCOPUS:85141890061

SN - 1083-7159

VL - 27

SP - E908-E911

JO - Oncologist

JF - Oncologist

IS - 11

ER -

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this